TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - NOVO-NORDISK B Share Price
Certificat
DE000CL7HDL3
| Real-time Boerse Frankfurt Warrants 06:55:06 07/06/2024 pm IST | ||
| 20.61 EUR | +2.03% |
|
| Current month | +6.54% | ||
| 1 month | +17.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 20.61 | +2.03% |
| 06/24/06 | 20.2 | +0.95% |
| 05/24/05 | 20.01 | +1.78% |
| 04/24/04 | 19.66 | +3.58% |
| 03/24/03 | 18.98 | +0.11% |
Real-time Boerse Frankfurt Warrants
Last update June 07, 2024 at 06:55 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | CL7HDL |
| ISIN | DE000CL7HDL3 |
| Date issued | 07/04/2020 |
| Strike | 218.8 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.61 € |
|---|---|
| Lowest since issue | 0.19 € |
| Spread | 0.01 € |
| Spread % | 0.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
973.3
DKK
Average target price
920.8
DKK
Spread / Average Target
-5.40%
- Stock Market
- Certificates
- Certificat
